MURFREESBORO, TN / ACCESSWIRE / January 8, 2025 / National Health Investors, Inc. (NYSE:NHI) announced a series of changes to…
Webinar to be held Wednesday, January 8, 2025, at 8am ESTREDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper…
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE,…
– Oversubscribed equity raise at US$0.625 per share capitalizes Company with a strong balance sheet– – Financing enables Vireo to…
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today,…
– $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance…
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with…
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed…
NIH Initiatives Will Enhance Generative AI Usage and Health Data Discoverability RESTON, Va., Dec. 11, 2024 /PRNewswire/ -- ICF (NASDAQ:ICFI),…
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant…